Diagnosis, treatment and prevention of 2019 novel coronavirus infection in children: experts' consensus statement (First Edition);儿童新型冠状病毒感染诊断, 治疗和预防专家共识(第一版)

Chinese Journal of Applied Clinical Pediatrics

Volumn 35, Issue 2, 2020, Pages 81-85

  Jiang, Yi ^a   Xu, Baoping ^a   Jin, Runming ^a   Zheng, Yuejie ^a   Xie, Zhengde ^a   Lin, Likai ^a   Shang, Yunxiao ^a   Lu, Xiaoxia ^a   Shu, Sainan ^a   Bai, Yan ^a   Deng, Jikui ^a   Lu, Min ^a   Ye, Leping ^a   Wang, Tianyou ^a   Wang, Yongyan ^a   Wang, Xuefeng ^a   Gao, Liwei ^a   Li, Xingwang ^a   Zhao, Dongchi ^a   Yang, Yonghong ^a   Shen, Kunling ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIAGNOSIS; PRIORITY JOURNAL; THERAPY;

EID: 85081963283     PISSN: 2095428X     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.2095-428X.2020.02.001     Document Type: Article

References (35)

1. 中华人民共和国国家卫生健康委员会.武汉市卫生健康委员会关于新型冠状病毒感染的肺炎情况通报[EB/OL].(2020-01-12)[2020-02-03].http://www.nhc.gov.cn/yjb/s3578/202001/9b26b91b313c44a8b0005d6a15519c9d.shtml. National Health Commission of the People's Republic of China. Report of novel coronavirus pneumonia by Wuhan Health Commission. [2020-01-12]. http://www.nhc.gov.cn/yjb/s3578/202001/9b26b91b313c44a8b0005d6a15519c9d.shtml.
2. Zhu N, Zhang D, Wang W,et al. A novel coronavirus from patients with pneumonia in China,2019. N Engl J Med, 2020, Epub ahead of print. DOI:10.1056/NEJMoa2001017.
3. 中华人民共和国国家卫生健康委员会.新型冠状病毒感染的肺炎诊疗方案(试行第五版)[EB/OL].(2020-02-05)[2020-02-05].http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml. National Health Commission of the People's Republic of China. Diagnosis and treatment plan of novel coronavirus pneumonia(Trial version 5). [2020-02-05]. http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml.
4. 湖北省医学会儿科学分会,武汉医学会儿科学分会,湖北省儿科医疗质量控制中心.湖北省儿童新型冠状病毒感染诊疗建议(试行第一版)[J].中国当代儿科杂志,2020,22(2):96-99.. Pediatric Branch of Hubei Medical Association, Pediatric Branch of Wuhan Medical Association, Pediatric Medical Quality Control Center of Hubei. Recommendation for the diagnosis and treatment of novel coronavirus infection in children in Hubei (Trial version 1). Chin J Contemp Pediatr, 2020, 22(2):96-99. DOI:10.7499/j.issn.1008-8830.2020.02.003.
5. Chan JF, Yuan S, Kok KH,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission:a study of a family cluster. Lancet, 2020, Epub ahead of print. DOI:10.1016/S0140-6736(20)30154-9.
6. Huang C, Wang Y, Li X,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China. Lancet, 2020, Epub ahead of print. DOI:10.1016/S0140-6736(20)30183-5.
7. Chen N, Zhou M, Dong X,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study. Lancet, 2020, Epub ahead of print. DOI:10.1016/S0140-6736(20)30211-7.
8. 李仲智,申昆玲,魏新苗,等.18例儿童严重急性呼吸综合征临床分析[J].中华儿科杂志,2003,41(8):574-577.. Li ZZ, Shen KL, Wei XM,et al. Clinical analysis of pediatric SARS cases in Beijing. Chin J Pediatr, 2003, 41(8):574-577. DOI:10.3760/j.issn.0578-1310.2003.08.005.
9. 杨永弘.关注严重急性呼吸综合征[J].中华儿科杂志,2003,41(6):401-402.. Yang YH. Pay attention to severe acute respiratory syndrome. Chin J Pediatr, 2003, 41(6):401-402. DOI: 10.3760/j.issn.0578-1310.2003.06.001.
10. 曾其毅,刘丽,曾华松,等.广州地区33例儿童严重急性呼吸综合征临床特点和治疗转归[J].中华儿科杂志,2003,41(6):408-412.. Zeng QY, Liu L, Zeng HS,et al. Clinical characteristics and prognosis of 33 children with severe acute respiratory syndrome in Guangzhou area. Chin J Pediatr, 2003, 41(6):408-412. DOI:10.3760/j.issn.0578-1310.2003.06.004.
11. Thabet F, Chehab M, Bafaqih H,et al. Middle East respiratory syndrome coronavirus in children. Saudi Med J, 2015, 36(4): 484-486. DOI:10.15537/smj.2015.4.10243.
12. 中华人民共和国国家卫生健康委员会.儿童社区获得性肺炎诊疗规范(2019年版)[EB/OL].(2019-02-11)[2020-02-03].http://www.nhc.gov.cn/yzygj/s7653/201902/bfa758ad6add48a599bc74b588a6e89a.shtml. National Health Commission of the People's Republic of China. Guideline for diagnosis and treatment of community-acquired pneumonia in children (2019 version). [2019-02-11]. http://www.nhc.gov.cn/yzygj/s7653/201902/bfa758ad6add48a599bc74b588a6e89a.shtml.
13. 中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委员会.儿童社区获得性肺炎管理指南(2013修订)(上) [J].中华儿科杂志,2013,51(10):745-752.. The Subspecialty Group of Respiratory Diseases, The Society of Pediatrics, Chinese Medical Association, The Editorial Board, Chinese Journal of Pediatrics. Guidelines for management of community acquired pneumonia in children(the revised edition of 2013)(Ⅰ). Chin J Pediatr, 2013, 51(10):745-752. DOI:10.3760/cma.j.issn.0578-1310.2013.10.006.
14. Harris M, Clark J, Coote N,et al. British thoracic society guidelines for the management of community acquired pneumonia in children:update 2011. Thorax, 2011, 66 ii1-i23. DOI:10.1136/thoraxjnl-2011-200598.
15. Bradley JS, Byington CL, Shah SS,et al. The management of community-acquired pneumonia in infants and children older than 3 months of age:clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis, 2011, 53(7): e25-76. DOI:10.1093/cid/cir531.
16. Wang BX, Fish EN. Global virus outbreaks:Interferons as 1st responders. Semin Immunol, 2019, 43 101300. DOI:10.1016/j.smim.2019.101300.
17. Al-Tawfiq JA, Momattin H, Dib J,et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus:an observational study. Int J Infect Dis, 2014, 20 42-46. DOI:10.1016/j.ijid.2013.12.003.
18. 王辉强,马琳琳,蒋建东,等.重组人干扰素α2b体外广谱抗呼吸道病毒药效学研究[J].药学学报,2014,49(11):1547-1553. Wang HQ, Ma LL, Jiang JD,et al. Recombinant human interferon alpha 2b broad-spectrum anti-respiratory viruses pharmacodynamics study in vitro. Acta Pharm Sin, 2014, 49(11):1547-1553.
19. Hijano DR, Siefker DT, Shrestha B,et al. Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy. Sci Rep, 2018, 8(1): 11034. DOI:10.1038/s41598-018-29456-w.
20. 申昆玲,尚云晓,张国成,等.α干扰素在儿科临床合理应用专家共识 [J].中华实用儿科临床杂志,2018,33(17):1301-1308.. Shen KL, Shang YX, Zhang GC,et al. Expert consensus on the rational application of interferon alpha in pediatrics. Chin J Appl Clin Pediatr, 2018, 33(17):1301-1308. DOI:10.3760/cma.j.issn.2095-428X.2018.17.006.
21. 国家卫生计生委儿童用药专家委员会,中华医学会儿科学分会呼吸学组,中国医师协会儿科医师分会儿童呼吸专业委员会,等.儿童喘息性疾病合理用药指南 [J].中华实用儿科临床杂志,2018,33(19):1460-1472.. The Expert Committee on Pediatric Medicine of National Health and Commission, National Health and Family Planning Commission of The People's Republic of China, Respiratory Group, Pediatric Section of Chinese Medical Association, Committee of Respiratory Disease, Pediatric Society of Chinese Physicians' Association,et al. Guidelines for rational drug use in children with wheezing disorders. Chin J Appl Clin Pediatr, 2018, 33(19):1460-1472. DOI:10.3760/cma.j.issn.2095-428X.2018.19.005.
22. 刘斌,尚云晓,卢叶丹.SD大鼠口鼻吸入重组人干扰素α2b注射液(假单胞菌)及辅料羟乙基淀粉40的安全性研究[J].国际儿科学杂志,2019,46(9):692-697.. Liu B, Shang YX, Lu YD. Safety of aerosol inhalation of recombinant human interferon alpha 2b injection (P.putida) and excipient hydroxyethyl starch 40 to healthy SD rats. Int J Pediatr, 2019, 46(9):692-697. DOI:10.3760/cma.j.issn.1673-4408.2019.09.018.
23. 中华人民共和国国家卫生健康委员会.手足口病诊疗指南(2018年版)[EB/OL].(2018-05-18)[2020-02-03].http://www.nhc.gov.cn/yzygj/s3594q/201805/5db274d8697a41ea84e88eedd8bf8f63.shtml. National Health Commission of the People's Republic of China. Diagnosis and treatment guideline on hand,foot and mouth disease (2018). [2018-05-18]. http://www.nhc.gov.cn/yzygj/s3594q/201805/5db274d8697a41ea84e88eedd8bf8f63.shtml.
24. 徐艳利,李颖,陈益平,等.重组人干扰素α2b喷雾剂治疗小儿手足口病有效性和安全性的多中心对照临床研究[J].中华传染病杂志,2018,36(2):101-106.. Xu YL, Li Y, Chen YP,et al. A multicenter controlled clinical study on the efficacy and safety of recombinant human interferon α2b spray in the treatment of hand,foot and mouth disease in children. Chin J Infect Dis, 2018, 36(2):101-106. DOI:10.3760/cma.j.issn.1000-6680.2018.02.008.
25. 中华医学会儿科学分会感染学组,国家感染性疾病医疗质量控制中心.疱疹性咽峡炎诊断及治疗专家共识(2019年版) [J].中华儿科杂志,2019,57(3):177-180.. The Subspecialty Group of Infectious Diseases, the Society of Pediatrics, Chinese Medical Association, National Center for Quality Control of Infectious Diseases. Expert consensus on diagnosis and treatment of herpangina (version 2019). Chin J Pediatr, 2019, 57(3):177-180. DOI:10.3760/cma.j.issn.0578-1310.2019.03.004.
26. 申昆玲,尚云晓,张贺,等.重组人干扰素α2b喷雾剂(假单胞菌)治疗儿童急性上呼吸道感染有效性和安全性多中心随机对照临床研究[J].中国实用儿科杂志,2019,34(12):1010-1016. Shen KL, Shang YX, Zhang H,et al. A multicenter randomized controlled clinical study on the efficacy and safety of recombinant human interferon α2b spray (P.putida) in treatment of acute upper respiratory tract infections in children. Chin J Pract Pediatr, 2019, 34(12):1010-1016.
27. 高虹,张丽兰,魏强,等.重组人干扰素α2b鼻腔喷雾剂预防治疗恒河猴感染SARS-CoV的试验研究[J].中华实验和临床病毒学杂志,2005,19(3):207-210.. Gao H, Zhang LL, Wei Q,et al. Preventive and therapeutic effects of recombinant IFN -α2b nasal spray on SARS-CoV infection in Macaca mulata. Chin J Exp Clin Virol, 2005, 19(3):207-210. DOI:10.3760/cma.j.issn.1003-9279.2005.03.002.
28. 于德宪,陈清,张丽兰,等.重组人干扰素α-2b喷雾剂预防SARS等呼吸道病毒感染的人群试验研究[J].中华实验和临床病毒学杂志,2005,19(3):216-219.. Yu DX, Chen Q, Zhang LL,et al. A field trial of recombinant human interferon α-2b for nasal spray to prevent SARS and other respiratory viral infections. Chin J Exp Clin Virol, 2005, 19(3):216-219. DOI:10.3760/cma.j.issn.1003-9279.2005.03.004.
29. Chu CM, Cheng VC, Hung IF,et al. Role of lopinavir/ritonavir in the treatment of SARS:initial virological and clinical findings. Thorax, 2004, 59(3): 252-256. DOI:10.1136/thorax.2003.012658.
30. 洛匹那韦利托那韦片说明书[EB/OL].(2017-07-07)[2020-02-03].https://www.jianke.com/product/222002.html. . Lopinavir and Ritonavir Tablets. [2017-07-07]. https://www.jianke.com/product/222002.html.
31. 纪晓光,赵艳红,张敏,等.阿比多尔抗SARS病毒的体外实验研究[J].解放军药学学报,2004,20(4):274-276.. Ji XG, Zhao YH, Zhang M,et al. The Experimental Study of the Anti-SARS-CoV Effect of Arbidole. Pharm J Chin PLA, 2004, 20(4):274-276. DOI: 10.3969/j.issn.1008-9926.2004.04.012.
32. 中华人民共和国国家卫生健康委员会.流行性感冒诊疗方案(2019年版)[EB/OL].(2019-11-13)[2020-02-03].http://www.nhc.gov.cn/yzygj/s7653p/201911/a577415af4e5449cb30ecc6511e369c7.shtml. National Health Commission of the People's Republic of China. Protocol for diagnosis and treatment of influenza(2019 revised version). [2019-11-13]. http://www.nhc.gov.cn/yzygj/s7653p/201911/a577415af4e5449cb30ecc6511e369c7.shtml.
33. World Health Organization.Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts[EB/OL].(2020-01-20)[2020-02-03].https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts.
34. The US Centers for Disease Control and Prevention.Interim guidance for persons who may have 2019 Novel Coronavirus (2019-nCoV) to prevent spread in homes and residential communities[EB/OL].(2020-02-01)[2020-02-03].https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-prevent-spread.htmlCDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fguidance-prevent-spread.html.
35. 中华人民共和国国家卫生健康委员会.新型冠状病毒传播途径与预防指南[EB/OL].(2020-01-27)[2020-02-03].http://www.nhc.gov.cn/jkj/s3578/202001/9e73060017d744aeafff8834fc0389f4.shtml. National Health Commission of the People's Republic of China. Transmission route and prevention guide of novel coronavirus. [2020-01-27]. http://www.nhc.gov.cn/jkj/s3578/202001/9e73060017d744aeafff8834fc0389f4.shtml.